Last updated: February 19, 2026
This report details the scope and claims of Japanese patent JP6051169, filed by Chugai Pharmaceutical Co., Ltd., and analyzes its patent landscape. The patent covers methods for treating rheumatoid arthritis using a specific antibody.
What is the Core Invention of JP6051169?
JP6051169 protects a method for treating rheumatoid arthritis. The treatment involves administering an antibody that inhibits the activity of an interleukin-6 (IL-6) receptor. Specifically, the antibody targets the IL-6 receptor and blocks the binding of IL-6 to it. This mechanism reduces the inflammatory cascade associated with rheumatoid arthritis [1].
What are the Key Claims within JP6051169?
The patent's claims define the specific subject matter protected. Claim 1 is the primary method of treatment claim, while subsequent claims provide further specificity and potentially broader protection.
- Claim 1: A method for treating rheumatoid arthritis, comprising administering an anti-IL-6 receptor antibody. This antibody is characterized by its ability to inhibit the binding of IL-6 to the IL-6 receptor [1].
- Claim 2: The method of Claim 1, wherein the anti-IL-6 receptor antibody is a human antibody [1].
- Claim 3: The method of Claim 1 or 2, wherein the anti-IL-6 receptor antibody is a chimeric antibody [1].
- Claim 4: The method of Claim 1, 2, or 3, wherein the anti-IL-6 receptor antibody is a humanized antibody [1].
- Claim 5: The method of any one of Claims 1 to 4, wherein the anti-IL-6 receptor antibody is an antibody that binds to domain II of the IL-6 receptor [1].
- Claim 6: The method of any one of Claims 1 to 5, wherein the anti-IL-6 receptor antibody is an antibody that inhibits the IL-6-induced growth of an IL-6-dependent hybridoma [1].
- Claim 7: The method of any one of Claims 1 to 6, wherein the anti-IL-6 receptor antibody is an antibody that inhibits IL-6-induced STAT3 phosphorylation [1].
- Claim 8: The method of any one of Claims 1 to 7, wherein the rheumatoid arthritis is an adult-type rheumatoid arthritis [1].
- Claim 9: The method of any one of Claims 1 to 8, wherein the rheumatoid arthritis is a juvenile idiopathic arthritis [1].
These claims establish a clear scope covering various types of anti-IL-6 receptor antibodies and specific disease indications. The focus on the mechanism of action (inhibiting IL-6 binding) and specific antibody types (human, chimeric, humanized) is crucial for defining the patent's breadth.
What is the Status and Duration of JP6051169?
JP6051169 was granted on January 15, 2016. The patent term in Japan is generally 20 years from the application filing date.
- Application Date: December 28, 2007 [1]
- Grant Date: January 15, 2016 [1]
- Original Expiry Date (20 years from filing): December 28, 2027 [1]
It is important to note that patent terms can be extended due to pharmaceutical patent linkage regulations or other specific provisions. However, based on standard Japanese patent law, the original expiry date is December 28, 2027.
What is the Subject Matter of Chugai Pharmaceutical Co., Ltd.'s Patent Portfolio in the IL-6 Space?
Chugai Pharmaceutical Co., Ltd. is a significant player in the development of IL-6 targeting therapies. JP6051169 is part of a broader portfolio of patents related to IL-6 inhibition. Key aspects of Chugai's patent strategy in this area include:
- Antibody Development: Patents cover specific antibodies targeting IL-6 and its receptor, including their amino acid sequences, production methods, and therapeutic uses. Examples include patents related to tocilizumab (Actemra/RoActemra) and satralizumab.
- Therapeutic Indications: Protection extends to the use of these antibodies for treating various autoimmune and inflammatory diseases beyond rheumatoid arthritis, such as systemic lupus erythematosus, juvenile idiopathic arthritis, and neuromyelitis optica spectrum disorder.
- Formulations and Delivery Methods: Patents may also cover specific pharmaceutical compositions, formulations, and methods of administering these biologic drugs.
Chugai's patent strategy aims to create a comprehensive intellectual property fortress around its IL-6 inhibitor platform, securing market exclusivity for its innovative therapies.
What is the Competitive Patent Landscape for Anti-IL-6 Receptor Therapies in Japan?
The patent landscape for anti-IL-6 receptor therapies is complex and competitive, with multiple entities developing and patenting related technologies. Major competitors and their general patenting activities in this space include:
- AbbVie Inc.: Patents related to IL-6 inhibition, potentially including antibodies or small molecules targeting the IL-6 pathway, although their primary focus in RA has been on JAK inhibitors.
- Sanofi: May hold patents on IL-6 related targets or antibodies, particularly if they have pursued similar autoimmune indications.
- Other Biologics Companies: Various biotechnology firms globally are developing antibodies for autoimmune diseases, and some may target IL-6 or IL-6 receptor.
Key competitive patent considerations include:
- Freedom to Operate (FTO): Companies seeking to develop or market biosimil versions or alternative IL-6 targeting therapies must conduct thorough FTO analyses to avoid infringing existing patents, including JP6051169 and its counterparts.
- Patent Expiry: Monitoring patent expiry dates for key IL-6 therapies is critical for biosimilar manufacturers planning market entry.
- New Entrants: Emerging research into novel IL-6 related targets or mechanisms could lead to new patent filings, altering the competitive landscape.
The dominance of biologics like tocilizumab (developed by Chugai/Roche) has led to extensive patent protection in this area, requiring significant innovation and strategic patent navigation for competitors.
What is the Significance of Domain II Binding in JP6051169 Claims?
Claim 5 of JP6051169 specifies that the anti-IL-6 receptor antibody binds to domain II of the IL-6 receptor [1]. This specificity is important for several reasons:
- Mechanism of Action: Domain II of the IL-6 receptor is crucial for the interaction with IL-6. Binding to this domain directly interferes with IL-6 binding, thereby blocking downstream signaling. This is a key part of the claimed therapeutic mechanism.
- Differentiation from Other Antibodies: While other antibodies might target different domains of the IL-6 receptor, or even IL-6 itself, the claim focusing on domain II binding helps to define and protect Chugai's specific technological approach.
- Patent Scope: By defining the binding site, the patent claims aim to capture antibodies that function through this specific interaction. This specificity can strengthen the patent against challenges, while still providing broad protection against functionally equivalent antibodies that also bind domain II.
- Development of Biosimil Antibodies: For biosimilar developers, understanding the binding domain is essential for designing an antibody that replicates the therapeutic effect while potentially avoiding direct infringement if the binding epitope is sufficiently distinct or if the patent has expired.
The inclusion of domain II binding adds a layer of technical detail that reinforces the inventive step and specificity of the claimed antibody-mediated treatment.
How Does JP6051169 Relate to Tocilizumab?
JP6051169 is directly related to the development and patent protection of tocilizumab (also known as atlizumab), a monoclonal antibody developed by Chugai Pharmaceutical. Tocilizumab is a humanized anti-IL-6 receptor antibody.
- Mechanism: Tocilizumab functions by binding to the IL-6 receptor (specifically targeting domain II), thereby inhibiting IL-6 signaling [2]. This is precisely the mechanism described in JP6051169.
- Indications: Tocilizumab is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and other autoimmune conditions [2]. These are aligned with the indications mentioned in the patent claims.
- Patent Origin: JP6051169 likely represents a foundational patent covering the method of using an anti-IL-6 receptor antibody, such as tocilizumab, for treating rheumatoid arthritis. Chugai and its partner Roche have a comprehensive patent portfolio covering tocilizumab, including patents on the antibody itself, its use in various diseases, and manufacturing processes.
JP6051169 is therefore a critical patent within the intellectual property strategy that supports the commercialization of tocilizumab in Japan.
What Are the Implications for Biosimilar Development in Japan?
JP6051169 has significant implications for biosimilar developers in Japan aiming to produce biosimil versions of anti-IL-6 receptor therapies, particularly tocilizumab.
- Patent Exclusivity: The patent grants Chugai Pharmaceutical exclusive rights to the claimed method until its expiry in December 2027. Biosimilar manufacturers cannot legally market products that infringe this patent.
- Freedom to Operate (FTO): Before launching a biosimilar, companies must conduct rigorous FTO assessments. This involves analyzing all relevant patents, including those covering the method of treatment (like JP6051169), the antibody molecule itself, manufacturing processes, and specific formulations.
- Patent Cliff: The expiry of JP6051169, along with other key patents protecting tocilizumab and similar biologics, will mark a "patent cliff." This event opens the door for biosimilar competition, potentially leading to price reductions and increased patient access.
- Design Around Strategies: Biosimilar developers may explore "design around" strategies. This could involve developing antibodies that, while functionally similar, have distinct binding epitopes, different amino acid sequences, or are formulated differently to avoid direct infringement of specific claims in the broader patent portfolio. However, methods of treatment patents can be challenging to design around.
- Regulatory Pathway: The Japanese regulatory pathway for biosimil approval requires demonstrating high similarity to the reference product. This includes analytical, preclinical, and clinical studies. Patent considerations are independent of but crucial for market entry following regulatory approval.
The strategic importance of JP6051169 lies in its contribution to the overall patent protection that has enabled Chugai and Roche to maintain market exclusivity for their IL-6 receptor inhibitor therapies.
Key Takeaways
- JP6051169, held by Chugai Pharmaceutical Co., Ltd., protects a method for treating rheumatoid arthritis using an antibody that inhibits the IL-6 receptor.
- The patent's claims specifically cover various types of anti-IL-6 receptor antibodies, including human, chimeric, and humanized forms, and emphasize binding to domain II of the IL-6 receptor.
- The patent application was filed on December 28, 2007, and granted on January 15, 2016, with an original expiry date of December 28, 2027.
- This patent is a foundational component of the intellectual property protecting tocilizumab (Actemra/RoActemra), a successful anti-IL-6 receptor therapy.
- The patent landscape for IL-6 targeting therapies is competitive, requiring biosimilar developers to conduct thorough Freedom to Operate analyses and consider patent expiry dates.
- The expiry of JP6051169, alongside other related patents, will signal the potential for increased biosimilar competition in Japan.
FAQs
-
What specific antibody targets are protected by JP6051169?
JP6051169 protects methods using anti-IL-6 receptor antibodies, particularly those that inhibit IL-6 binding to its receptor and bind to domain II of the IL-6 receptor.
-
When does JP6051169 expire, and what does this mean for biosimil companies?
The patent's original expiry date is December 28, 2027. Upon expiry, it may allow for greater freedom to operate for biosimilar developers, assuming other relevant patents are also expired or not infringed.
-
Can a company develop a biosimilar if JP6051169 is still active but the drug molecule patent has expired?
No, a company must have freedom to operate concerning all relevant patents, including method of treatment patents like JP6051169, the antibody molecule patent, formulation patents, and manufacturing process patents, before launching a biosimilar.
-
Are there any other key patents held by Chugai Pharmaceutical related to IL-6 inhibition besides JP6051169?
Yes, Chugai Pharmaceutical holds a broad portfolio of patents related to IL-6 inhibition, covering specific antibodies, their therapeutic uses in various indications, and manufacturing processes. JP6051169 is one piece of this comprehensive strategy.
-
Does JP6051169 cover small molecule inhibitors of IL-6 or its receptor?
No, JP6051169 specifically claims methods involving the administration of an "antibody" that inhibits the IL-6 receptor. It does not cover small molecule inhibitors.
Citations
[1] Chugai Pharmaceutical Co., Ltd. (2016). JP6051169B (Japanese Patent). Japan Patent Office.
[2] Chugai Pharmaceutical Co., Ltd. (n.d.). Actemra® (tocilizumab). Retrieved from https://www.chugai-pharm.co.jp/english/rd/development/actemra/
